Mapi Pharma

Formulations That Meet Unmet Patient Needs

Focused on long acting
depot injections

Developing Finished Dosage Forms and a Portfolio of APIs

Fully integrated GMP
manufacturing facilities

Pipeline of Multiple Late Stage Products

In Phase III for RMS and Phase II for
PPMS for treating MS

We are a clinical stage pharmaceutical company, developing complex active pharmaceutical ingredients.

Focus

Our main focus is on developing long acting depot injectable drugs.

Programs

Our lead programs are GA Depot for treating various forms of MS and long acting Pregabalin (Lyrica^®) for pain.

Latest News

Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis

August 7, 2023

FDA assigns PDUFA target action date of March 8, 2024 New Drug Application supported by positive Phase III efficacy and safety clinical trial results Milestone builds upon Viatris’ long-standing and continued commitment toward addressing the unmet needs of the MS...

Viatris and Mapi Pharma to Highlight Latest Results of Multiple Sclerosis Research at American Academy of Neurology 75th Annual Meeting

April 24, 2023

Meeting program to feature latest clinical findings for GA Depot and showcase commitment to improving care for people living with multiple sclerosis (MS) PITTSBURGH, April 24, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Mapi...